SEC Form 4 · accession 0001636282-26-000099
Spyre Therapeutics, Inc. · SYRE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Cameron Turtle
Officer — Chief Executive Officer · Director
Period of report
Aug 3, 2026
Accepted (ET)
Aug 5, 2026 · 9:31 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001636282
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Aug 3, 2026 | S | 800 | $93.97 | D | 581,740 | D | |
| Common StockF4,F3 | Aug 3, 2026 | S | 7,157 | $95.10 | D | 574,583 | D | |
| Common StockF5,F3 | Aug 3, 2026 | S | 5,635 | $95.93 | D | 568,948 | D | |
| Common StockF6,F3 | Aug 3, 2026 | S | 1,392 | $96.82 | D | 567,556 | D | |
| Common StockF7,F3 | Aug 3, 2026 | S | 16 | $97.46 | D | 567,540 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.
- F2The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $93.42 to $94.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
- F3Includes 58,108 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date.
- F4The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $94.44 to $95.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F5The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $95.45 to $96.44, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F6The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $96.45 to $97.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F7The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $97.46 to $97.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.